Cutler Jim E, Deepe George S, Klein Bruce S
Department of Pediatrics and Microbiology, Louisiana State University Health Sciences, and Research Institute for Children at Children's Hospital, New Orleans, Louisiana, 70118 USA.
Nat Rev Microbiol. 2007 Jan;5(1):13-28. doi: 10.1038/nrmicro1537. Epub 2006 Dec 11.
The dramatic increase in fungal diseases in recent years can be attributed to the increased aggressiveness of medical therapy and other human activities. Immunosuppressed patients are at risk of contracting fungal diseases in healthcare settings and from natural environments. Increased prescribing of antifungals has led to the emergence of resistant fungi, resulting in treatment challenges. These concerns, together with the elucidation of the mechanisms of protective immunity against fungal diseases, have renewed interest in the development of vaccines against the mycoses. Most research has used murine models of human disease and, as we review in this article, the knowledge gained from these studies has advanced to the point where the development of vaccines targeting human fungal pathogens is now a realistic and achievable goal.
近年来真菌疾病的急剧增加可归因于医学治疗手段的增强及其他人类活动。免疫抑制患者在医疗环境及自然环境中都有感染真菌疾病的风险。抗真菌药物处方量的增加导致了耐药真菌的出现，从而带来了治疗挑战。这些问题，再加上对真菌疾病保护性免疫机制的阐明，重新激发了人们对开发抗真菌病疫苗的兴趣。大多数研究使用人类疾病的小鼠模型，正如我们在本文中所综述的，从这些研究中获得的知识已经发展到现在开发针对人类真菌病原体的疫苗是一个现实且可实现的目标的阶段。
